Endocrine, metabolic & immune disorders drug targets

Semaglutide's possible impact on muscle and bone health linked to GLP-1 receptor levels

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Semaglutide's impact on bone and muscle health remains unclear.

  • Semaglutide is used for glycemic control and weight loss.
  • The potential effects of semaglutide on the musculoskeletal system have not been fully established.
  • This study examines the relationship between GLP1R and bone and muscle health.
  • Mendelian Randomization is utilized to assess these impacts.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Jan '25
Possible Links Between GLP1R Activation, Lower Blood Sugar, and Common Aging Diseases
cited by 1 paper
journal article
Jun '25
Summary of studies comparing how well GLP-1 receptor agonists work for weight loss
top 10% journal
cited by 5 papers
systematic review
Mar '25
Possible links between diabetes drugs targeting GLP-1 receptors and mental health from genetic analysis
top 20% journal
cited by 6 papers
meta-analysis
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 98 papers
journal article
Dec '25
Link between diabetes drugs that activate GLP-1 receptors and mood disorders using real-world data and genetic analysis
top 5% journal
journal article
May '25
Possible links between diabetes drugs targeting GLP-1 receptors and irregular heartbeats or cardiac arrest
top 20% journal
cited by 3 papers
journal article
Sep '25
Genetic evidence that activating GLP1R and GIPR reduces binge drinking and alcohol-related traits across populations
top 2% journal
cited by 5 papers
journal article
Apr '25
Links between glucagon-like peptide-1 receptor activators, inflammation, and kidney disease from genetic evidence
top 30% journal
cited by 2 papers
meta-analysis

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief